Milasen (IMAGE)
Caption
An unprecedented case at Boston Children's Hospital shows that it's possible to do something that's never been done before: identify a patient's unique mutation, design a customized drug to bypass it, manufacture and test the drug, and obtain permission from the Food and Drug Administration (FDA) to begin treating the patient -- all in less than one year.
Credit
Boston Children’s Hospital
Usage Restrictions
None
License
Licensed content